Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2024, 6(5); doi: 10.25236/IJFM.2024.060510.

Whole brain radiotherapy plus erlotinib for the treatment of non-small cell lung cancer patients with brain metastases: A meta-analysis and network pharmacology mechanisms


Jiaying Zhang1, Xin Liu2, Jinfeng Shang2

Corresponding Author:
Jiaying Zhang

1School of Medicine, Ankang University, Ankang City, Shaanxi Province, China

2School of Chinese Materia Medica, Beijing University of Chinese Medicines, Beijing, China


The apparent increase in the incidence of non-small cell lung cancer (NSCLC) with brain metastases is due to the employment of advanced diagnostic methods and increased public health consciousness. The chief treatment for multiple brain metastases is whole-brain radiotherapy (WBRT), erlotinib is permitted as first line of therapy for terminal NSCLC patients at present. However, no comprehensive statistical and systematic analysis has been performed to verify the clinical effectiveness and security of this treatment. Consequently, we conducted a meta-analysis to assess effectiveness and safety of WBRT plus erlotinib in the cure of brain metastases from NSCLC. To investigate the mechanism of erlotinib in the treatment of brain metastases from NSCLC by network pharmacology. The results of this meta-analysis indicated that WBRT combined with erlotinib is an effective and safe treatment of brain metastases from NSCLC. WBRT combined with erlotinib can remarkably improve the overall response rate and disease control rate, and extend the 1-year survival rate, the progression-free survival, the median survival time and medium PFS. This study reveals the mechanism of multi-target and multi-pathway action of erlotinib in the treatment of brain metastases from NSCLC, and provides a basis for the study of clinical anti-tumor action mechanism of erlotinib.


Whole-brain radiotherapy, Erlotinib, Brain metastases, Non-small cell lung cancer, Meta-analysis, Network pharmacology

Cite This Paper

Jiaying Zhang, Xin Liu, Jinfeng Shang. Whole brain radiotherapy plus erlotinib for the treatment of non-small cell lung cancer patients with brain metastases: A meta-analysis and network pharmacology mechanisms. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 5: 67-80. https://doi.org/10.25236/IJFM.2024.060510.


[1] Huan Huang, Jihong Liu, Qinglian Meng, Guozhong Niu. Multidrug resistance protein and topoisomerase 2 alpha expression in non-small cell lung cancer are related with brain metastasis postoperatively [J]. Int. J. Clin. Exp. Pathol, 2015(8):11537–11542.

[2] Duan H, Zheng SY, Zhou T, Cui HJ, Hu KW. Temozolomide plus whole brain radiotherapy for the treatment of non-small-cell lung cancer patients with brain metastases: A protocol of an updated systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(5):18455. 

[3] Deng X, Zheng Z, Lin B, et al. The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases[J]. BMC Cancer, 2017, 17(1):42. 

[4] Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial[J]. Int J Radiat Oncol Biol Phys, 2009,73(4):1069-1076. 

[5] Hongqing Zhuang, Jun Wang, Lujun Zhao, Zhiyong Yuan, Ping Wang.The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma[J].International Journal of Cancer, 2013,133:2277–2283.

[6] Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials[J]. BMJ, 2011, 343:5928. 

[7] Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur. J.Epidemiol, 2010, 25:603–605. 

[8] Yong Xin, Wenwen Guo, Chun Sheng Yang. Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung Cancer[J]. Cancer Medicine, 2018, 7: 981–990.

[9] Jill S Barnholtz-Sloan, Andrew E Sloan, Faith G Davis, Fawn D Vigneau, Ping Lai, Raymond E Sawaya. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System[J]. J Clin Oncol, 2004, 22:2865–2872.

[10] Harvey J Mamon, Beow Yong Yeap, Pasi A Jänne, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation[J]. J Clin Oncol, 2005, 23: 1530–1537.

[11] Ali RH, Taraboanta C, Mohammad T, Hayes MM, Ionescu DN. Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma-case series and literature review[J]. Virchows Arch, 2018, 472(5):771-777.

[12] Sang Young Kim, Chang Ki Hong, Tae Hoon Kim, et al. Efficacy of surgical treatment for brain metastasis in patients with non-small cell lung cancer[J]. Yonsei Medical Journal, 2015, 56: 103–111.

[13] Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5):1312-1318. 

[14] Daniel Chua, Maciej Krzakowski, Christos Chouaid, et al. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study[J]. Clin. Lung Cancer ,2010,11:176–181.

[15] Matthias Preusser, David Capper, Aysegül Ilhan-Mutlu, et al. Brain metastases: pathobiology and emerging targeted therapies[J]. Acta Neuropathologica, 2012,123: 205–222.

[16] Juhász E, Kim JH, Klingelschmitt G, Walzer S. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer[J]. Eur J Cancer,2013,49(6):1205-1215. 

[17] Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, et al. Erlotinib in previously treated non-small-cell lung cancer[J]. N Engl J Med, 2005,353:123–132.

[18] Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study[J]. Lancet Oncol,2010,11:521–529.

[19] Caicun Zhou, Yi-Long Wu, Gongyan Chen, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011,12:735–742.

[20] Rafael Rosell, Enric Carcereny, Radj Gervais, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13: 239–246.

[21] Prakash Chinnaiyan, Shyhmin Huang, Geetha Vallabhaneni, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) [J]. Cancer Res,2005,65:3328–3335.

[22] Lai CS, Boshoff C, Falzon M, Lee SM.Complete response to erlotinib treatment in brain metastases from recurrent NSCLC[J]. Thorax,2006,61:91.

[23] Britta Weber, Michael Winterdahl, Ashfaque Memon, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor[J]. J Thoracic Oncol,2011,6:1287–1289.

[24] Hata A, Kaji R, Fujita S, Katakami N. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer[J]. J Thoracic Oncol,2011,6:653–654.

[25] R Porta, J M Sánchez-Torres, L Paz-Ares, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation[J]. Eur Respir J, 2011, 37:624–631.

[26] Yimao Zhang, John Laterra, Martin G. Pomper.Hedgehog Pathway Inhibitor HhAntag691 Is a Potent Inhibitor of ABCG2/BCRP and ABCB1/Pgp[J]. Neoplasia, 2009, 11:96–101.

[27] Chihiro Endo-Tsukude, Ji-Ichiro Sasaki, Sho Saeki, et al. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters[J].Biol Pharm Bull, 2018,41:47–56.

[28] Mao Q, Wang L, Liang Y, et al. CYP3A5 suppresses metastasis of lung adenocarcinoma through ATOH8/Smad1 axis[J]. Am J Cancer Res,2020,10:3194-3211. 

[29] Ogheneochukome Lolodi, Yue-Ming Wang, William C Wright, Taosheng Chen. Differential Regulation of CYP3A4 and CYP3A5 and Its Implication in Drug Discovery[J]. Curr Drug Metab, 2017, 18: 1095–1105. 

[30] Wenlong Li, Rolf W Sparidans, Yaogeng Wang, et al. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and Cytochrome P450-3A(CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib[J]. International Journal of Cancer,2018,143:2029-2038. 

[31] Masahiro Ohgami, Takayuki Kaburagi, Atsuhiko Kurosawa, Masato Homma. Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer [J]. Lung Cancer, 2016, 11:9-10.

[32] Min Kyoung Kim, Jeong Yee, Yoon Sook Cho, Hong Won Jang, Ji Min Han, Hye Sun Gwak. Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study[J]. BMC Cancer,2018,18: 988.

[33] Svedberg A, Vikingsson S, Vikström A, et al. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients[J]. Br J Clin Pharmacol, 2019,85:1704-1709.